Prior PD‐(L)1 inhibitor treatment could reprogram the tumor microenvironment by normalizing tumor vasculature, improving tissue perfusion and decreasing intratumoral hypoxia in a T cell‐dependent manner, which may potentially sensitize the tumor to TRT and meanwhile makes surrounding healthy lung tissue more fragile to attack of TRT.13, 28, 29, 30. This evidence concerns the gene CD274 and neoplasm.